Clinical trial
NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)
NCT00142454 · Ludwig Institute for Cancer Research, Other · Completed
Key facts
| NCT number | NCT00142454 |
|---|---|
| Title | NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting) |
| Official title | NY-ESO-1 Protein Vaccination in Malignant Melanoma Administered With Imiquimod as Adjuvant |
| Lead sponsor | Ludwig Institute for Cancer Research, Other |
| Collaborators | Cancer Research Institute, New York City |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Malignant Melanoma |
| Intervention type | Biological, Drug |
| Interventions | Imiquimod, NY-ESO-1 protein |
| Enrollment | 9 |
| Start date | Aug 24, 2005 |
| Primary completion | Apr 25, 2006 |
| Completion | Apr 25, 2006 |
| First posted | Sep 2, 2005 |
| Last update posted | Oct 10, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: